Mustafa Bashir

Overview:

Hepatobiliary and pancreatic imaging
Liver cancer (hepatocellular carcinoma)
Fatty liver, NAFLD, and NASH
Chronic liver disease and cirrhosis
Pancreatic cancer
Technical development in MRI
Quantitative imaging

Positions:

Associate Professor of Radiology

Radiology, Abdominal Imaging
School of Medicine

Associate Professor in the Department of Medicine

Medicine, Gastroenterology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 2004

University of Iowa

Grants:

Imaging Core Lab for Madrigal Protocol MGL-3196-05 (A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis)

Administered By
Radiology, Abdominal Imaging
Awarded By
Madrigal Pharmaceuticals
Role
Principal Investigator
Start Date
End Date

A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986036 (PEG-FGF21) IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND STAGE 3 LIVER FIBROSIS.

Administered By
Radiology, Abdominal Imaging
Awarded By
Bristol-Myers Squibb Company
Role
Principal Investigator
Start Date
End Date

3V2640-CLIN-005 A Phase 2, Multi-Center, Single-Blind, Randomized Placebo Controlled Study of TVB-2640 in Subjects with Non-Alcoholic Steatohepatitis

Administered By
Radiology, Abdominal Imaging
Awarded By
Diabetes & Endocrinology Consultants, PC
Role
Principal Investigator
Start Date
End Date

A randomized, open label, phase 1b study to evaluate safety, PK and PD signals of DUR-928 in patients with Non-Alcoholic Steatohepatitis (NASH)

Administered By
Radiology, Abdominal Imaging
Awarded By
High Point Clinical Trial Center
Role
Principal Investigator
Start Date
End Date

A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients with Histologically Confirmed Nonalcoholic Steatohepatit

Administered By
Medicine, Gastroenterology
Awarded By
NGM Biopharmaceuticals
Role
Co-Principal Investigator
Start Date
End Date

Publications:

Correction to: Artificial intelligence in assessment of hepatocellular carcinoma treatment response.

Authors
Spieler, B; Sabottke, C; Moawad, AW; Gabr, AM; Bashir, MR; Do, RKG; Yaghmai, V; Rozenberg, R; Gerena, M; Yacoub, J; Elsayes, KM
MLA Citation
Spieler, Bradley, et al. “Correction to: Artificial intelligence in assessment of hepatocellular carcinoma treatment response.Abdom Radiol (Ny), vol. 46, no. 8, Aug. 2021, pp. 3672–73. Pubmed, doi:10.1007/s00261-021-03098-5.
URI
https://scholars.duke.edu/individual/pub1482741
PMID
34028593
Source
pubmed
Published In
Abdom Radiol (Ny)
Volume
46
Published Date
Start Page
3672
End Page
3673
DOI
10.1007/s00261-021-03098-5

LI-RADS treatment response algorithm for detecting incomplete necrosis in hepatocellular carcinoma after locoregional treatment: a systematic review and meta-analysis using individual patient data.

PURPOSE: To perform a systematic review and meta-analysis using individual patient data to investigate the diagnostic performance of Liver Imaging Reporting and Data System (LI-RADS) Treatment Response (TR) algorithm for detecting incomplete necrosis on pathology. METHODS: PubMed and EMBASE were searched from Jan 1, 2017 until October 14, 2020. Studies reporting diagnostic accuracy of LI-RADS TR algorithm on CT or MRI for detecting incomplete necrosis on pathology as a reference standard were included. Sensitivity and specificity were pooled using random-effects model. Subgroup analyses were performed for locoregional treatment (LRT) type and imaging modality. RESULTS: Six studies (393 patients, 534 lesions) were included. Pooled sensitivity was 0.56 (95% confidence interval [CI] 0.43-0.69) and specificity was 0.91 (95%CI 0.84-0.96). Pooled sensitivity was highest using arterial phase hyperenhancement (APHE) (0.67 [95%CI 0.51-0.81]), followed by washout (0.43 [95%CI 0.26-0.62]) and enhancement similar to pretreatment (0.24 [95%CI 0.15-0.36]). Among lesions with incomplete necrosis, 2% (95%CI 0.00-0.05) manifested as washout but no APHE; 0% (95% CI 0.00-0.02) as enhancement similar to pretreatment without both APHE and washout. Pooled sensitivity was lower after ablation than embolization (0.42 [95%CI, 0.28-0.57] vs. 0.65 [95%CI, 0.53-0.77], p = 0.033). MRI and CT were comparable (p = 0.783 and 0.290 for sensitivity and specificity). CONCLUSIONS: LI-RADS TR algorithm shows moderate sensitivity and high specificity for detecting incomplete necrosis after LRT. APHE is the dominant criterion, a washout contributes to small but meaningful extent, while the contribution of enhancement similar to pretreatment may be negligible. LRT type may affect performance of the algorithm.
Authors
Kim, T-H; Woo, S; Joo, I; Bashir, MR; Park, M-S; Burke, LMB; Mendiratta-Lala, M; Do, RKG
MLA Citation
URI
https://scholars.duke.edu/individual/pub1482742
PMID
34027566
Source
pubmed
Published In
Abdom Radiol (Ny)
Volume
46
Published Date
Start Page
3717
End Page
3728
DOI
10.1007/s00261-021-03122-8

Multisite multivendor validation of a quantitative MRI and CT compatible fat phantom.

PURPOSE: Chemical shift-encoded magnetic resonance imaging enables accurate quantification of liver fat content though estimation of proton density fat-fraction (PDFF). Computed tomography (CT) is capable of quantifying fat, based on decreased attenuation with increased fat concentration. Current quantitative fat phantoms do not accurately mimic the CT number of human liver. The purpose of this work was to develop and validate an optimized phantom that simultaneously mimics the MRI and CT signals of fatty liver. METHODS: An agar-based phantom containing 12 vials doped with iodinated contrast, and with a granular range of fat fractions was designed and constructed within a novel CT and MR compatible spherical housing design. A four-site, three-vendor validation study was performed. MRI (1.5T and 3T) and CT images were obtained using each vendor's PDFF and CT reconstruction, respectively. An ROI centered in each vial was placed to measure MRI-PDFF (%) and CT number (HU). Mixed-effects model, linear regression, and Bland-Altman analysis were used for statistical analysis. RESULTS: MRI-PDFF agreed closely with nominal PDFF values across both field strengths and all MRI vendors. A linear relationship (slope = -0.54 ± 0.01%/HU, intercept = 37.15 ± 0.03%) with an R2 of 0.999 was observed between MRI-PDFF and CT number, replicating established in vivo signal behavior. Excellent test-retest repeatability across vendors (MRI: mean = -0.04%, 95% limits of agreement = [-0.24%, 0.16%]; CT: mean = 0.16 HU, 95% limits of agreement = [-0.15HU, 0.47HU]) and good reproducibility using GE scanners (MRI: mean = -0.21%, 95% limits of agreement = [-1.47%, 1.06%]; CT: mean = -0.18HU, 95% limits of agreement = [-1.96HU, 1.6HU]) were demonstrated. CONCLUSIONS: The proposed fat phantom successfully mimicked quantitative liver signal for both MRI and CT. The proposed fat phantom in this study may facilitate broader application and harmonization of liver fat quantification techniques using MRI and CT across institutions, vendors and imaging platforms.
Authors
Zhao, R; Hernando, D; Harris, DT; Hinshaw, LA; Li, K; Ananthakrishnan, L; Bashir, MR; Duan, X; Ghasabeh, MA; Kamel, IR; Lowry, C; Mahesh, M; Marin, D; Miller, J; Pickhardt, PJ; Shaffer, J; Yokoo, T; Brittain, JH; Reeder, SB
MLA Citation
Zhao, Ruiyang, et al. “Multisite multivendor validation of a quantitative MRI and CT compatible fat phantom.Med Phys, vol. 48, no. 8, Aug. 2021, pp. 4375–86. Pubmed, doi:10.1002/mp.15038.
URI
https://scholars.duke.edu/individual/pub1484213
PMID
34105167
Source
pubmed
Published In
Med Phys
Volume
48
Published Date
Start Page
4375
End Page
4386
DOI
10.1002/mp.15038

Week 4 Liver Fat Reduction on MRI as an Early Predictor of Treatment Response in Participants with Nonalcoholic Steatohepatitis.

Background Pharmacologic treatment of nonalcoholic steatohepatitis (NASH) is long term in nature; thus, early noninvasive treatment response assessment is important for therapeutic decision making. Purpose To investigate potential early predictors of the 12-week treatment response estimated by using the MRI-based proton-density fat fraction (PDFF). Materials and Methods In this secondary analysis of a prospective phase Ib clinical trial evaluating a candidate treatment (MET409, a farnesoid X receptor agonist) for NASH, participants were analyzed at baseline and at 4 and 12 weeks after either active treatment with MET409 or placebo treatment between June 2019 and January 2020. Correlation and multiple linear regression analyses were used to identify clinical, laboratory, and imaging predictors of the relative PDFF change at week 12 (W12). Multivariate logistic regression analysis was used to develop predictive models for an at least 30% relative PDFF reduction at W12, a well-validated indicator of histologic improvement. Model performance was characterized by using area under the receiver operating characteristic curve (AUC) analysis, sensitivity, and specificity. Results A total of 48 participants were analyzed (median age, 57 years; age range, 40-62 years; 32 women), among whom 30 received MET409 and 18 received a placebo. The week 4 (W4) relative changes in PDFF (regression coefficient = 1.24, P < .001) and the serum alkaline phosphatase (ALP) level (regression coefficient = -0.29, P = .03) were predictors of the W12 relative PDFF change. An at least 19.3% relative PDFF reduction at W4 yielded an AUC of 0.98 (sensitivity, 89%; specificity, 95%) for predicting an at least 30% relative PDFF reduction at W12. The addition of ALP to the predictive model did not improve model performance. Conclusion In participants with nonalcoholic steatohepatitis enrolled in a phase Ib treatment trial, the relative change in the MRI-based proton-density fat fraction (PDFF) at week 4 was highly predictive of the treatment response estimated by using the week 12 MRI-based PDFF. © RSNA, 2021 Online supplemental material is available for this article.
Authors
MLA Citation
Jiang, Hanyu, et al. “Week 4 Liver Fat Reduction on MRI as an Early Predictor of Treatment Response in Participants with Nonalcoholic Steatohepatitis.Radiology, vol. 300, no. 2, Aug. 2021, pp. 361–68. Pubmed, doi:10.1148/radiol.2021204325.
URI
https://scholars.duke.edu/individual/pub1484214
PMID
34060937
Source
pubmed
Published In
Radiology
Volume
300
Published Date
Start Page
361
End Page
368
DOI
10.1148/radiol.2021204325

MR Imaging of Diffuse Liver Disease.

The liver performs many vital functions for the human body. It stores essential vitamins and minerals, such as iron and vitamins A, D, K, and B12. It synthesizes proteins, such as blood clotting factors, albumin, and glycogen, as well as cholesterol, carbohydrates, and triglycerides. Additionally, it acts as a detoxifier, metabolizing and helping to clear alcohol, drugs, and ammonia. Typical MR imaging protocols for liver imaging include T2-weighted, chemical shift imaging, and precontrast and postcontrast T1-weighted sequences. This article discussed MR imaging of diffuse liver diseases and their typical imaging findings.
Authors
Marks, RM; Fowler, KJ; Bashir, MR
MLA Citation
Marks, Robert M., et al. “MR Imaging of Diffuse Liver Disease.Magn Reson Imaging Clin N Am, vol. 29, no. 3, Aug. 2021, pp. 347–58. Pubmed, doi:10.1016/j.mric.2021.05.004.
URI
https://scholars.duke.edu/individual/pub1488598
PMID
34243922
Source
pubmed
Published In
Magn Reson Imaging Clin N Am
Volume
29
Published Date
Start Page
347
End Page
358
DOI
10.1016/j.mric.2021.05.004